en.hdbuzz.net
Read the original →
uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130
uniQure Plans BLA Submission for AMT-130 Gene Therapy in Huntington’s Disease
clinicaltrialvanguard.com · Jun 18, 2026 Standard
Skyhawk reports encouraging 12-month results for oral Huntington’s disease drug SKY-0515 – HDBuzz
en.hdbuzz.net · Jun 1, 2026 Standard
Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam – HDBuzz
en.hdbuzz.net · May 4, 2026 Standard
Putting it in print: oral drug branaplam lowered huntingtin, but safety concerns halted development – HDBuzz
en.hdbuzz.net · Feb 12, 2026 Standard
A hitch in the stitch reveals why DNA sequence patterns matter in Huntington’s disease – HDBuzz
en.hdbuzz.net · Feb 9, 2026 Standard
The First Domino Falls: AMT-130 Gene Therapy Slows Huntington’s in Landmark Trial – HDBuzz
en.hdbuzz.net · Sep 24, 2025 Standard